[ad_1]
As a first step, the FDA approved a drug specifically designed to reduce excessive sweating. ] Associated Press reports. Most people do not know that this common disorder exists, and for those who have it, excessive sweating is clinically known as hyperhidrosis. The condition can be localized in a particular area of an individual's anatomy or it can be diffuse, which means that it affects most of the skin.
Many of us sweat when we are hot, stressed or when we exercise. Excessive sweating of people with hyperhidrosis far exceeds episodes of normal sweating.
Axillary hyperhidrosis is another form of the disease, and it involves excessive localized sweating in the armpits. Another still is palmoplantar hyperhidrosis localized to the palms and soles of the feet. These two types of hyperhidrosis cause at least one episode a week, and they occur during waking hours. Sweating cases in these cases often occur on both sides of the body.
According to the Mayo Clinic, hyperhidrotic people can sweat so much that they soak in their clothes, and sweat can even drip from their hands. Excessive sweating can disrupt normal daily activities and can even cause embarrbadment and social anxiety. Hyperhidrosis can even affect educational goals and further work.
Other complications of excessive sweating include skin infections because people who sweat profusely are often more prone to this type of infection.
Excessive sweating is called Qbrexza. When it is made available to patients, it will most likely help them to lead a better social life. The drug works by blocking the activation of the sweat glands, and it is contained in a tissue that is wiped on the skin every day.
@US_FDA approves the first drug developed to reduce excessive underarms # Sweating a common condition, inducing anxiety. Qbrexza will be on sale in October. Maker @DermiraInc does not disclose his medicine #Price . https://t.co/HkWqEPGRVm pic.twitter.com/X4eFKFyql7
– Linda A. Johnson (@LindaJ_onPharma) June 29, 2018
It is estimated that 15.3 million In the United States, people suffer from hyperhidrosis, but only one in four people gets treatment. Current treatments for excessive sweating include prescription antiperspirants, oral medications, botox injections, microwave destruction and, as a last resort, surgery that interrupts selected nerve pathways.
Qbrexa has known side effects: constipation, blurred vision, dry mouth, burning skin and itching, throat and head pain, and dry eyes, mouth and skin.
The manufacturer of Qbrexa, Dermira Inc., refused to disclose the price of the drug, as drug manufacturers sometimes do. It is expected that Qbrexa will go on sale in October.
In a study conducted by Dermira it was reported that 53 percent of people said that Qbrexza reduced their sweat production by half, compared with 28 percent non-drug tissue
[ad_2]
Source link
